Hollingshead Brett D, Tomlinson Lindsay, Finley Jim, Doshna Colleen, Ritenour Casey, Barricklow Jason, Oppenheimer Stacey R, O'Neil Shawn P, Moore Jessica L, Patterson Nathan Heath, Nicholson Sarah P, Norris Jeremy L, Caprioli Richard M, Beaumont Kevin, King-Ahmad Amanda J, Vispute Saurabh, Cook Jon C, Radi Zaher, Schuler Maik
Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA.
Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA.
Regul Toxicol Pharmacol. 2021 Jul;123:104934. doi: 10.1016/j.yrtph.2021.104934. Epub 2021 Apr 16.
Systemic toxicity assessments for oral or parenteral drugs often utilize the concentration of drug in plasma to enable safety margin calculations for human risk assessment. For topical drugs, there is no standard method for measuring drug concentrations in the stratum basale of the viable epidermis. This is particularly important since the superficial part of the epidermis, the stratum corneum (SC), is nonviable and where most of a topically applied drug remains, never penetrating deeper into the skin. We investigated the relative concentrations of a prototype kinase inhibitor using punch biopsy, laser capture microdissection, and imaging mass spectrometry methods in the SC, stratum basale, and dermis of minipig skin following topical application as a cream formulation. The results highlight the value of laser capture microdissection and mass spectrometry imaging in quantifying the large difference in drug concentration across the skin and even within the epidermis, and supports use of these methods for threshold-based toxicity risk assessments in specific anatomic locations of the skin, like of the stratum basale.
口服或注射用药物的全身毒性评估通常利用血浆中的药物浓度来进行人体风险评估的安全边际计算。对于局部用药物,目前尚无标准方法来测量活表皮基底层中的药物浓度。这一点尤为重要,因为表皮的表层即角质层(SC)是无生命的,局部应用的大部分药物都留在该层,不会深入皮肤。我们采用打孔活检、激光捕获显微切割和成像质谱方法,研究了一种原型激酶抑制剂以乳膏制剂形式局部应用于小型猪皮肤后,在角质层、基底层和真皮中的相对浓度。结果突出了激光捕获显微切割和质谱成像在量化皮肤甚至表皮内药物浓度巨大差异方面的价值,并支持将这些方法用于基于阈值的皮肤特定解剖部位(如基底层)的毒性风险评估。